Tafamidis

Tafamidis is a medication used in the treatment of transthyretin-mediated amyloidosis (ATTR), a rare, progressive, and fatal disease. It is marketed under the brand names Vyndaqel and Vyndamax by Pfizer.

Mechanism of Action

Tafamidis works by stabilizing the transthyretin (TTR) protein, preventing it from misfolding and forming amyloid plaques. These plaques are the cause of the symptoms seen in ATTR.

Uses

Tafamidis is used in the treatment of both hereditary and wild-type ATTR. It is also used in the treatment of cardiomyopathy and polyneuropathy associated with ATTR.

Side Effects

Common side effects of Tafamidis include urinary tract infection, diarrhea, and upper respiratory tract infection. Serious side effects can include heart failure and stroke.

History

Tafamidis was first approved for use in the European Union in 2011. It was approved for use in the United States by the Food and Drug Administration (FDA) in 2019.

See Also

• Transthyretin
• Amyloidosis
• Pfizer

‎

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian